Business Context and Reporting Period
Company: Ultragenyx Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 9, 2015
Event: Entry into a Material Definitive Agreement (Lease Amendment).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or general debt levels. It discloses specific financial obligations related to a new lease agreement:
- New Monthly Rent: Approximately $26,600 for the expansion space.
- New Letter of Credit Requirement: Approximately $425,000.
- Increased Letter of Credit (Total): $762,072 (includes a $286,790 increase to the existing lease security).
Material Changes
The Company executed Addendum #4 to its Standard Lease with Condiotti Enterprises, Inc., effective March 9, 2015. Key changes include:
- Expansion of Premises: Addition of approximately 20,000 square feet at 52 Leveroni Court, Novato, California (16,800 sq. ft. office, 3,500 sq. ft. warehouse).
- Lease Term: Commences May 1, 2015, and expires April 30, 2019.
- Financial Obligations: Implementation of new rent payments and increased security deposits via letters of credit.
Outlook, Risks, and Management Commentary
Management Intent: The Company intends to install leasehold improvements to the new expansion space.
Risks/Contingencies: The filing notes that base monthly rent will increase annually beginning on the first anniversary of the commencement date. The Company is required to extend insurance coverages to the new space. No other risks or unusual items are disclosed in this specific report.
Investor Verification Checklist
- Verify the impact of the new $26,600 monthly rent obligation on the Company's operating cash flow.
- Confirm the availability of liquidity to post the required $425,000 letter of credit and the $286,790 increase to the existing letter of credit.
- Review the timeline for leasehold improvements and associated capital expenditure requirements.
- Check subsequent filings for the actual commencement of rent payments on May 1, 2015.